Incyte Corporation (INCY) Earnings & Analysis

Latest quarter

Incyte reported Q3 FY2026 revenue of $1.6 billion, above the consensus estimate of $1.5 billion. Adjusted EPS was −$3.60, compared with the consensus estimate of −$3.99. Revenue rose 14.0% from $1.4 billion a year earlier.

The company reported Opzelura net sales of $254.9 million, while its filing attributed the product’s sales increase to higher volume and pricing. The filing said increased U.S. patient demand in atopic dermatitis and vitiligo drove the volume increase. For Jakafi, Incyte said higher volume was partly offset by lower pricing; paid demand increased 12% in the quarter.

Incyte reported diluted EPS of −$3.86, compared with $2.11 a year earlier. Its filing said research and development expenses included $1.23 billion for acquired in-process research and development assets from the Vega acquisition. Operating margin was −45.5%, versus 32.5% a year earlier, and free cash flow was −$691.0 million, compared with $519.6 million.

Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.

What management said on the call

On Incyte’s Q2 call, before the latest quarter, CEO William Meury said increased demand and higher net sales across the portfolio had driven sales growth. He described Jakafi as a funding source for the pipeline and product launches, while saying growth in the core business excluding Jakafi was supported by multiple products and near-term launches.

Meury said the Jakafi XR launch depended on both coverage and adoption. He expected physician adoption to build gradually through the remainder of 2026 as coverage expanded and doctors gained experience with the formulation, with acceleration throughout 2027.

On Opzelura, Meury said resolution of the Medicaid rebate matter improved the product’s gross-to-net profile. He expected prescription growth to translate more efficiently into net sales, but described the pricing and reimbursement environment as dynamic and said maintaining access remained a priority.

Asked about business development and spending as a share of sales, Meury said Incyte would consider opportunities meeting its strategic and financial criteria and could be patient otherwise. He said the company was not managing to a fixed margin percentage and would stop investments if their circumstances changed or performance fell short of expectations.

Chief Scientific Officer Pablo Cagnoni discussed the company’s oncology programs in response to analyst questions. He said Incyte had initiated a phase three pancreatic cancer trial of its G12D inhibitor with chemotherapy and wanted a larger, more mature patient cohort to assess the program. On colorectal cancer, Cagnoni said the company was pursuing a combination with an EGFR inhibitor and described a separate TGF-beta by PD-1 program that could be given alongside full-dose bevacizumab.

Guidance

In its Q3 results release, Incyte raised its FY2026 total net-sales guidance to $5,210 - $5,300 million, from $5,130,000,000 to $5,260,000,000 on the Q2 call. The release raised the hematology and oncology net-sales outlook to $890 - $910 million, from 860 to 890 million on that call. Incyte also raised its Opzelura net-sales guidance to $1,100 - $1,120 million, from $1,050,000,000 to $1,100,000,000 on the Q2 call.